Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy

International Immunopharmacology

Volumn 2, Issue 13-14, 2002, Pages 1823-1832

  Spillmann, Frank ^a   Altmann, Christine ^a   Scheeler, Michael ^a   Barbosa, Marcos ^a   Westermann, Dirk ^a   Schultheiss, Heinz Peter ^a   Walther, Thomas ^a   Tschöpe, Carsten ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Aortic banding; B1 receptor; B2 receptor; Bradykinin; Diabetes mellitus; Myocardial infarction; Streptozotocin

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; MESSENGER RNA; STREPTOZOCIN; BRADYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIABETES MELLITUS; HEART CATHETER; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE DP-DT; HEMODYNAMIC MONITORING; LEFT CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RIBONUCLEASE PROTECTION ASSAY; STREPTOZOCIN DIABETES; THORACIC AORTA; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSURE; SPRAGUE DAWLEY RAT; SYSTOLE; UPREGULATION;

ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIAL INFARCTION; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; RNA, MESSENGER; SYSTOLE; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 0036892383     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00174-1     Document Type: Article

References (40)

1. Tschöpe C., Schultheiss H.-P., Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J. Cardiovasc. Pharmacol. 39:2002;478-487.
2. Regoli D., Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 55:1980;866-867.
3. Faussner A., Bathon J.M., Proud D. Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation. Immunopharmacology. 45:1999;:13-20.
4. Marceau F., Hess J.F., Bachvarov D.R. The B1 receptors for kinins. Pharmacol. Rev. 50:1998;357-386.
5. Tschöpe C., Gohlke P., Zhu Y.Z., Linz W., Schölkens B.et al. Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. J. Card. Fail. 3:1997;133-148.
6. Tschöpe C., Heringer-Walther S., Walther T. Regulation of the kinin receptors after induction of myocardial infarction: a mini-review. Braz. J. Med. Biol. Res. 33:2000;701-708.
7. Phagoo S.B., Poole S., Leeb-Lundberg L.M. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol. Pharmacol. 56:1999;325-333.
8. Sabourin T., Morissette G., Bouthillier J., Levesque L., Marceau F. Expression of kinin B(1) receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-kappa B. Am. J. Physiol. Heart Circ. Physiol. 283:2002;H227-H237.
9. Dean R., Murone C., Lew R.A., Zhuo J., Casley D.et al. Localization of bradykinin B2 binding sites in rat kidney following chronic ACE inhibitor treatment. Kidney Int. 52:1997;1261-1270.
10. Marin-Castano M.E., Schanstra J.P., Neau E., Praddaude F., Pecher C.et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 105:2002;627-632.
11. Tschöpe C., Heringer-Walther S., Koch M., Spillmann F., Wendorf M.et al. Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J. Hypertens. 18:2000;223-228.
12. Tschöpe C., Walther T., Yu M., Reinecke A., Koch M.et al. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology. 44:1999;35-42.
13. Allard M.F., Emanuel P.G., Russell J.A., Bishop S.P., Digerness S.B.et al. Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts. Am. J. Physiol. Heart Circ. Physiol. 267:1994;H66-H74.
14. Tschöpe C., Heringer-Walther S., Koch M., Spillmann F., Wendorf M.et al. Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br. J. Pharmacol. 129:2000;1537-1538.
15. Kimura E., Hashimoto K., Furakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion a coronary artery. Am. Heart J. 85:1973;635-647.
16. Hashimoto K., Hirose M., Furukawa K., Hayakawa H., Kimura E. Changes in hemodynamic and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn. Heart J. 18:1977;679-680.
17. Hashimoto K., Hamamoto H., Honda Y., Hirose M., Furukawa S.et al. Changes in components of kinin system and hemodynamic in acute myocardial infarct. Am. Heart J. 95:1978;619-626.
18. 9-bradykinin release following reperfusion of the ischemic rat heart. Br. J. Pharmacol. 115:1995;476-478.
19. Marceau F., Larrivee J.-F., Bouthillier J., Bachvarova M., Houleset al. Effect of endogenous kinins, prostanoids, and NO on kinin B1 and B2 receptor expression in the rabbit. Am. J. Physiol. 277:1999;R1568-R1578.
20. Yue P., Massie B.M., Simpson P.C., Long C.S. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am. J. Physiol. 44:1998;H250-H258.
21. Hu K., Goudron P., Anders H.-J., Weidemann F., Turschner O.et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc. Res. 39:1998;401-412.
22. Yang X.P., Liu Y.H., Mehta D., Cavasin M.A., Shesely E.et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ. Res. 88:2001;1072-1079.
23. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham Study. Diabetes. 34:1974;29-34.
24. Tooke J.E. The microcirculation in diabetes. Diabet. Med. 4:1987;189-196.
25. Sharma J.N., Uma K., Yosof A.P. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int. J. Cardiol. 63:1998;229-235.
26. Kiff R.J., Gardiner S.M., Compton A.M., Bennett T. Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. Br. J. Pharmacol. 103:1991;1357-1362.
27. Vallejo S., Angulo J., Peiro C., Nevado J., Sanchez-Ferrer A.et al. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia. 43:2000;83-90.
28. Tschöpe C., Escher F., Spillmann F., Rehfeld U., Hauke D.et al. Transgenic expression of human kallikrein prevents altered left ventricular function, the decline in sarcoplasmatic reticulum pump activity and the rise in cardiac collagen content in diabetic rats. Circulation. 112(II):2000;267.
29. Cloutier F., Couture R. Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br. J. Pharmacol. 130:2000;375-385.
30. Christopher J., Velarde V., Zhang D., Mayfield D., Mayfield R.K.et al. Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 280:2001;H1537-H1546.
31. Mage M., Pecher C., Neau E., Cellier E., Dos Reiss M.L.et al. Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can. J. Physiol. Pharmacol. 80:2002;328-333.
32. Lechleitner M., Koch T., Herold M., Dzien A., Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J. Int. Med. 248:2000;67-76.
33. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 102:2000;470-479.
34. Brull D., Dhamrait S., Myerson S., Erdmann J., Regitz-Zagrosek V.et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 358:2001;1155-1156.
35. McAllister B.S., Leeb-Lundberg F., Olson M.S. Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. Am. J. Physiol. 265:1993;C477-C484.
36. Ishigai Y., Mori T., Ikeda T., Fukuzawa A., Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am. J. Physiol. 273:1997;H2659-H2663.
37. Emanueli C., Maestri R., Corradi D., Marchione R., Minasi A.et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation. 100:1999;2359-2365.
38. Silva J.A. Jr., Araujo R.C., Baltatu O., Oliveira S.M., Tschöpe C.et al. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J. 14:2000;1858-1860.
39. Yayama K., Hiyoshi H., Okamoto H. Expressions of bradykinin B2-receptor, kallikrein and kininogen mRNAs in the heart are altered in pressure-overload cardiac hypertrophy in mice. Biol. Pharm. Bull. 24:2001;34-38.
40. Schunkert H., Dzau V.J., Tang S.S., Hirsch A.T., Apstein C.S., Lorell B.H. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J. Clin. Invest. 86:1990;1913-1920.